Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma (SE:HNSA)
:HNSA
Earnings Data
Report Date
Apr 17, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-2.61Last Year’s EPS
-4.15Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 06, 2025
|% Change Since: -35.46%
|Next Earnings Date:Apr 17, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant sales growth and expansion in European markets, along with progress in clinical trials. However, revenue was impacted by provisions and the company continues to face volatility in sales and operational losses.Company Guidance
In the Hansa Biopharma Year End and Fourth Quarter 2024 Report call, the company reported a total revenue of SEK 220.9 million for 2024, with full-year IDEFIRIX sales at SEK 189.7 million, marking an 83% increase over the prior year. However, after accounting for a SEK 49.6 million provision, the total revenue adjusted to SEK 171.3 million, representing a 28% increase from the previous year. The company also highlighted significant progress in clinical trials, including the Phase 3 study in anti-GBM and a Phase 2 trial for Crigler-Najjar Syndrome, alongside positive data from the HANSA-5487 IgG-cleaving enzyme study. They secured reimbursement in three additional European markets, bringing the total to 18, and emphasized their ongoing efforts to expand IDEFIRIX's clinical utilization and market presence in Europe and beyond. Additionally, they are preparing for regulatory engagements regarding their new candidate, HNSA-5487, in myasthenia gravis, with data readouts expected in 2025.Strong IDEFIRIX Sales Growth
Full-year IDEFIRIX sales totaled SEK 189.7 million, representing an 83% increase over the prior year, excluding provisions. Including provisions, sales were SEK 140.1 million, a 35% increase year-over-year.
Expansion in Europe
Reimbursement secured in three additional European markets, now totaling 18 markets, including the five largest in Europe.
Pipeline Progress
Completed enrollment in Phase 3 study in anti-GBM and initiated a Phase 2 trial in Crigler-Najjar Syndrome. Positive results in HANSA-5487 first-in-human study showing potential in chronic autoimmune diseases.
---
SE:HNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SE:HNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 06, 2025 | kr33.62 | kr27.10 | -19.39% |
| Oct 17, 2024 | kr40.16 | kr41.28 | +2.79% |
| Jul 18, 2024 | kr46.56 | kr38.80 | -16.67% |
| Apr 18, 2024 | kr29.48 | kr29.06 | -1.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Hansa Biopharma (SE:HNSA) report earnings?
Hansa Biopharma (SE:HNSA) is schdueled to report earning on Apr 17, 2025, TBA Not Confirmed.
What is Hansa Biopharma (SE:HNSA) earnings time?
Hansa Biopharma (SE:HNSA) earnings time is at Apr 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hansa Biopharma stock?
The P/E ratio of Hansa Biopharma AB is N/A.
What is SE:HNSA EPS forecast?
SE:HNSA EPS forecast for the fiscal quarter 2025 (Q1) is -2.61.
---